Cromos Pharma, where the patients are


Premier Research names Drouet executive director, Oncology Europe

Monday, January 23, 2012 12:36 PM

Premier Research Group has appointed Etienne Drouet executive director, Oncology Europe. Drouet will play a leading role in the operations, strategic planning and corporate development of Premier Research’s growing portfolio of oncology businesses.

More... »

CRF Health eCOA webinar series

ICON named sole provider of central lab services to Shire

Monday, January 9, 2012 01:45 PM

CRO ICON has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

More... »

Icon boosts its presence in Asia with acquisition of Chinese CRO BeijingWits Medical Consulting

Monday, December 19, 2011 10:13 AM

Now that many mid-tier CROs have been acquired by either equity investment firms or other CROs and the trend has slowed, a new form of consolidation is emerging. Robust CROs are rounding out their offerings with small but strategic acquisitions to make them bigger, stronger and more complete. The ultimate goal: to continue winning lucrative strategic outsourcing agreements from sponsors.  

More... »

ICON to acquire BeijingWits Medical Consulting

Monday, December 12, 2011 01:21 PM

ICON has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting, a CRO in China. The transaction is expected to close in the first quarter of 2012.

More... »

Survey: Sponsor’s choice of central lab affects investigator’s satisfaction with trial experience

Monday, December 12, 2011 09:04 AM

The choice of a central lab can greatly affect a principal investigator’s satisfaction level while conducting a clinical trial. 

More... »

Tang joins ICON Development Solutions

Monday, November 28, 2011 11:29 AM

ICON's Development Solutions division has named Dr. Daniel Tang general manager, Asia Pacific. Tang will lead the development of ICON’s early phase activities across the region, including bioanalytical laboratory services, and the development of strong links with key opinion leaders for early phase clinical testing.

More... »

Tasly Pharmaceuticals selects ICON for phase III T89 trial

Monday, November 21, 2011 04:52 PM

ICON has been selected by Tasly Pharmaceuticals for the company’s global phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States. Dantonic pill is a botanical product for the treatment of chronic stable angina pectoris due to coronary heart disease. It is a modernized version of a traditional Chinese herbal medicine and was approved by the State Food and Drug Administration (SFDA) of China in 1993. Since then, more than 2 billion doses have been used by over 10 million patients. 

More... »

Survey: ICON Medical Imaging rated top provider

Thursday, November 17, 2011 01:14 PM

Dublin-based ICON has reported that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.

More... »

ICON's DOCS expands with four new offices in Europe

Wednesday, November 16, 2011 10:11 AM

ICON's resourcing division, DOCS, has expanded in Europe by opening four new offices: in Milan, Italy; Budapest, Hungary; Brussels, Belgium and Berlin, Germany. This latest expansion brings the total number of DOCS offices in Europe to 22.

More... »

ICON, Empire Genomics partner to develop personalized medicines

Wednesday, November 9, 2011 08:02 AM

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Empire Genomics, a provider of genomic technologies that enable personalized medicine to be realized, have formed a strategic alliance.

More... »

CenterWatch Data Library



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs